Trikafta 50-25-37.5 MG/75 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCPF3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,708
Award facts
- Contract value 100% obligated
- $37,707.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $37,707.90 firm fixed-price delivery order from the Defense Logistics Agency on December 30, 2025, for Trikafta 50-25-37.5 mg/75 mg tablets (84-count unit dose packaging). This delivery order was issued without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The award is associated with DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense healthcare facilities worldwide. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, was awarded on November 13, 2025, and establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply branded and generic prescription drugs, biologics, and medical consumables globally.
This delivery order represents one of numerous awards issued to DMS Pharmaceutical Group under the PPV-G GEN V contract, reflecting the company's established performance record in supplying specialized pharmaceutical products to military healthcare operations. The company's product portfolio encompasses oncology treatments, immunosuppressants, vaccines, emergency medications, and routine pharmaceuticals, positioning it as a critical supplier within the federal military medical system. With no identified subcontractors and funding provided solely by the Defense Logistics Agency, the contract demonstrates DMS Pharmaceutical Group's direct capability to fulfill diverse pharmaceutical requirements across the Department of Defense's global healthcare network.
Quick answers
Who was awarded contract SPE2DR26FCPF3?
SPE2DR26FCPF3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FCPF3 worth?
The government has obligated $37,708 on SPE2DR26FCPF3.
Is contract SPE2DR26FCPF3 an order under another contract?
Yes. SPE2DR26FCPF3 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPF3 competed?
The extent of competition for SPE2DR26FCPF3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award